Back

CASCADES, a novel SOX2 super-enhancer associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma multiforme

Shahzad, U.; Li, C.; Johnston, M.; Wang, J. J.; Sabha, N.; Varn, F. S.; Riemenschneider, A.; Krumholtz, S.; Meda, P.; Smith, C.; Karamchandani, J.; Watts, J. K.; Verhaak, R. G. W.; Gallo, M.; Rutka, J. T.; Das, S.

2020-09-06 cancer biology
10.1101/2020.09.05.284349 bioRxiv
Show abstract

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, with a median survival of just over one year. The failure of available treatments to achieve remission in patients with GBM has been attributed to the presence of cancer stem cells (CSCs), which are thought to play a central role in tumor development and progression and serve as a treatment-resistant cell repository capable of driving tumor recurrence; in fact, the property of "stemness" itself may be responsible for treatment resistance. In this study, we identify a novel lncRNA, Cancer stem cell associated distal enhancer of SOX2 (CASCADES) that functions as an epigenetic regulator in glioma CSCs (GSCs). CASCADES is expressed in IDH-wild type GBM and significantly enriched in GSCs. Knockdown of CASCADES in GSCs results in differentiation towards a neuronal lineage in a cell- and cancer-specific manner. Bioinformatics analysis reveals that CASCADES functions as a super-enhancer associated lncRNA epigenetic regulator of SOX2. Our findings identify CASCADES as a critical regulator of stemness in GSCs and represent a novel epigenetic and therapeutic target for disrupting the cancer stem cell compartment in GBM.

Matching journals

The top 15 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 10%
10.0%
Similar papers in this journal
2
Neuro-Oncology
◐ 36 papers in training set
Top 0.2%
5.6%
Similar papers in this journal
3
Neoplasia
○ 23 papers in training set
Top 0.1%
4.1%
Similar papers in this journal
4
Genome Research
● 468 papers in training set
Top 2%
3.6%
Similar papers in this journal
5
Epigenetics
○ 50 papers in training set
Top 0.2%
3.3%
Similar papers in this journal
6
iScience
○ 1154 papers in training set
Top 6%
3.3%
7
Life Science Alliance
● 285 papers in training set
Top 1%
3.2%
8
Scientific Reports
○ 3612 papers in training set
Top 36%
2.8%
9
PLOS ONE
● 5266 papers in training set
Top 38%
2.8%
10
Acta Neuropathologica Communications
○ 89 papers in training set
Top 0.8%
2.5%
11
Communications Biology
○ 993 papers in training set
Top 10%
2.2%
12
Nature Communications
○ 5641 papers in training set
Top 41%
2.2%
13
Molecular Cancer
○ 16 papers in training set
Top 0.1%
2.2%
14
Cell Reports
○ 1498 papers in training set
Top 16%
2.2%
15
EMBO Reports
○ 263 papers in training set
Top 3%
1.9%
50% of probability mass above
16
Journal of Biological Chemistry
○ 690 papers in training set
Top 5%
1.7%
17
Epigenetics & Chromatin
52 papers in training set
Top 0.4%
1.5%
18
Life Sciences
○ 27 papers in training set
Top 0.6%
1.5%
19
Cells
○ 249 papers in training set
Top 4%
1.5%
20
RNA Biology
○ 78 papers in training set
Top 0.8%
1.5%
21
Oncogenesis
○ 12 papers in training set
Top 0.2%
1.5%
22
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 33%
1.1%
23
Biology Open
● 156 papers in training set
Top 2%
1.1%
24
Molecular Oncology
○ 55 papers in training set
Top 1%
1.1%
25
Molecular Cancer Research
● 49 papers in training set
Top 1%
1.0%
26
Glia
○ 81 papers in training set
Top 1%
1.0%
27
Molecular and Cellular Biology
○ 47 papers in training set
Top 0.7%
0.9%
28
Cancers
○ 213 papers in training set
Top 4%
0.9%
29
NAR Cancer
◐ 37 papers in training set
Top 0.7%
0.9%
30
Stem Cells
◐ 31 papers in training set
Top 0.7%
0.9%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.